Atopic Dermatitis Plaque Psoriasis
A man driving a car with a female passenger A man driving a car with a female passenger
Not actual patients/caregiver.

Results from the open-label long-term extension study

VTAMA cream provided skin clearance and disease control of atopic dermatitis for patients down to 2 years of age.1

Not actual patients/caregiver.
A mom and son reading together
Not actual patients/caregiver.

Clinically proven to deliver
consecutive time off treatment1

728 patients with mild, moderate, or severe atopic dermatitis entered the ADORING 3 48-week, open-label, long-term extension (LTE) study of VTAMA.

Patients who entered the study with vIGA-ADTM≥1 used VTAMA daily and patients with vIGA-AD=0 stopped VTAMA. If patients achieved vIGA-AD=0 during the study, they stopped VTAMA until vIGA-AD≥2 occurred. When vIGA-AD≥2 occurred, patients restarted VTAMA.1

View Study Design

~2.5 consecutive treatment-free months (80 days):

In the 48-week, open-label, LTE study, atopic dermatitis patients (n=378) who entered with or achieved clear skin (vIGA-AD=0) maintained an average duration of ~80 consecutive days during the first treatment-free interval1,‡

*Including patients who entered with vIGA-AD=0 (n=58) or vIGA-AD=1 (n=189), and vIGA-AD≥2 who achieved 0 or 1 (n=347).1

†Including patients who entered with vIGA-AD=0 (n=58) and patients entering with vIGA-AD≥1 who achieved vIGA-AD=0 at least once during the open-label LTE study (n=320).1

‡Maintenance of clear or almost clear skin (vIGA-AD=0 or 1) off treatment, after first achieving complete disease clearance (vIGA-AD=0) and discontinuing treatment.

A child playing with her teddy bear
Not an actual patient.

Favorable and consistent
safety profile1

  • No new safety signals and there were low rates of study discontinuations due to treatment-emergent adverse events1
  • Long-term application of VTAMA demonstrated favorable local tolerability, even on sensitive skin areas including the face and neck1

Treatment-Emergent Adverse Events of Special Interest (AESIs) From the Open-Label Long-Term Extension Study1

AESI
Overall
N=728, n (%)
Contact dermatitis
11 (1.5)
Follicular event§
102 (14.0)
Headache
27 (3.7)
  • The most frequent TEAEs included folliculitis (12.1%), nasopharyngitis (6.9%), and upper respiratory tract infection (6.9%); trial discontinuations due to TEAEs were low (2.6%)1
  • AESI of follicular events, contact dermatitis, and headache were mostly mild or moderate and associated with low discontinuation rates (1.0%, 0.4%, and 0%, respectively)1

Demonstrated safety for long-term use1

There were no new safety signals with long-term tapinarof use in the LTE study, including in young children1

TEAE, treatment-emergent adverse event.

§Includes folliculitis, follicular eczema, keratosis pilaris, milia, and application site folliculitis.1

×

ADORING 3 Study Design

Study design of ADORING 3
Study design of ADORING 3
Off treatment1,2

Patients who entered the open-label LTE study with or achieved vIGA-AD=0 during the LTE study had VTAMA treatment temporarily discontinued

On treatment1,2

Patients who entered the open-label LTE study with vIGA-AD≥1 or with disease worsening (vIGA-AD≥2) during the LTE study were treated with VTAMA until vIGA-AD=0 was achieved (or Week 48)

Safety and tolerability1,2
  • Treatment-emergent adverse events (TEAEs)
  • Adverse events of special interest (AESIs)
  • Local tolerability as assessed by investigator and patient (or caregiver)
Efficacy1,2
  • Achievement of vIGA-AD=0
  • Achievement of vIGA-AD=0 or 1
  • Treatment-free interval: mean duration of maintenance of clear or almost clear skin off treatment, after first achieving complete disease clearance and discontinuing treatment

LTE, long-term extension; MUPK, maximal usage pharmacokinetics; PP-NRS, Peak Pruritus-Numeric Rating Scale; QD, once-daily; vIGA-AD, Validated Investigator Global Assessment for Atopic Dermatitis. vIGA-AD is a trademark of Eli Lilly and Co.

*Pediatric patients aged 2-17 years with mild AD (vIGA-AD=2), or moderate or severe AD, that did not meet inclusion criteria for ADORING 1 and ADORING 2.

References: 1. Bissonnette R, Stein Gold L, Kircik L, et al. Skin clearance, duration of treatment-free interval, and safety of tapinarof cream 1% once daily: results from ADORING 3, a 48-week phase 3 open-label extension trial in adults and children down to 2 years of age with atopic dermatitis. J Am Acad Dermatol. 2025;93(3):707-714. 2. Bissonnette R, Stein Gold L, Kircik L, et al. Skin clearance, duration of treatment-free interval, and safety of tapinarof cream 1% once daily: results from ADORING 3, a 48-week phase 3 open-label extension trial in adults and children down to 2 years of age with atopic dermatitis. J Am Acad Dermatol. 2025;S0190-9622(25):supplement.

Safety and Tolerability

For patients down to 2 years of age
Once-Daily Dosing

See more info on VTAMA dosing

INDICATION: VTAMA® (tapinarof) cream, 1% is an aryl hydrocarbon receptor (AhR) agonist indicated for the topical treatment of atopic dermatitis in adults and pediatric patients 2 years of age and older.

SELECTED SAFETY INFORMATION

Adverse Events: In atopic dermatitis, the most common adverse reactions (incidence ≥1%) were: upper respiratory tract infection, folliculitis, lower respiratory tract infection, headache, asthma, vomiting, ear infection, pain in extremity, and abdominal pain.

INDICATION: VTAMA® (tapinarof) cream, 1% is an aryl hydrocarbon receptor (AhR) agonist indicated for the topical treatment of atopic dermatitis in adults and pediatric patients 2 years of age and older.

SELECTED SAFETY INFORMATION

Adverse Events: In atopic dermatitis, the most common adverse reactions (incidence ≥1%) were: upper respiratory tract infection, folliculitis, lower respiratory tract infection, headache, asthma, vomiting, ear infection, pain in extremity, and abdominal pain.

Before prescribing VTAMA cream, please read the Prescribing Information.

Reference: 1. Bissonnette R, Stein Gold L, Kircik L, et al. Skin clearance, duration of treatment-free interval, and safety of tapinarof cream 1% once daily: results from ADORING 3, a 48-week phase 3 open-label extension trial in adults and children down to 2 years of age with atopic dermatitis. J Am Acad Dermatol. 2025;93(3):707-714.

Back to top